Quantcast

Latest Adalimumab Stories

2011-06-28 06:01:00

LONDON, June 28, 2011 /PRNewswire/ -- Rheumatoid arthritis treatment Humira will assume Lipitor's crown as the world's biggest selling drug, while Pfizer will cling on to its ranking as the biggest seller of prescription medicines through to 2016, according to the World Preview 2016 (second edition) report published today by EvaluatePharma, the premier provider of pharma and biotech analysis. Lipitor's patent expiry this year precipitates the steepest decline in the...

2011-06-13 07:00:00

MEMPHIS, June 13, 2011 /PRNewswire/ -- Humira defect lawyers filed a lawsuit against Abbott Laboratories in federal court today claiming Abbott's blockbuster drug, Humira, caused a fungal infection resulting in the near-death of a Tennessee man. Army veteran Fred Delano was prescribed Humira in October of 2008 for psoriatic arthritis. After taking the drug for two and-a-half months, Delano was hospitalized and diagnosed with disseminated histoplasmosis, an extremely dangerous side...

2011-06-08 11:07:00

NEW YORK, June 8, 2011 /PRNewswire/ -- One of the major annual rheumatology conferences, the European League Against Rheumatism's Congress (EULAR), was held May 25-28 in London. Citeline, Inc., reviewed the trends and highlights from clinical trial results reported at EULAR, noting that approved biologics in rheumatoid arthritis dominated the program, comprising roughly 25% of clinical trial abstracts presented. Updates from long-term trials for approved biologics in RA--including...

2011-05-25 15:14:53

Study findings suggest that it may be possible to identify candidates Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease control in many patients, and may also offer the opportunity to change future treatment options for some. Results of a study of 1032 patients with early (less than one year), active RA initially assessed response to treatment after...

2011-05-10 08:00:00

ABBOTT PARK, Ill., May 10, 2011 /PRNewswire/ -- Abbott's (NYSE: ABT) HUMIRA® (adalimumab) met its primary endpoint of clinical remission in a Phase III study of adult patients with moderate to severe ulcerative colitis. Results were presented at the Digestive Disease Week (DDW) scientific conference in Chicago. Ulcerative colitis (UC) is a chronic autoimmune disease that causes inflammation and ulceration in the lining of the colon or large intestine. It is estimated...

2011-05-09 13:44:40

Health outcomes explored at DDW 2011 Adalimumab (ADA), a drug often prescribed for women with Crohn's disease, actively crosses the placenta during the final trimester of pregnancy and remains in a newborn's bloodstream for at least three months, researchers at the University of California San Francisco have found. The new study has implications for pregnant women and their obstetricians and pediatricians because ADA is known to decrease the immune system's ability to fight infection. Infants...

2011-05-09 07:00:00

CHICAGO, May 9, 2011 /PRNewswire/ -- New study findings showed that treatment with STELARA® (ustekinumab) induced and maintained clinical response in patients with moderate to severe Crohn's disease who had previously failed or were intolerant to at least one tumor necrosis factor (TNF) antagonist. Investigators presented findings from a Phase 2b study at Digestive Disease Week, which showed nearly 40 percent of patients receiving STELARA 6 mg/kg achieved clinical...

2011-04-20 06:24:00

ABBOTT PARK, Ill., April 20, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2011. Diluted earnings per share, excluding specified items, were $0.91, reflecting 12.3 percent growth. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.55, including costs associated with acquisition integration, cost-reduction initiatives and acquired in-process R&D. Worldwide sales increased 17.4...

2011-04-15 15:39:00

SILVER SPRING, Md., April 15, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Actemra (tocilizumab), given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in children ages 2 years and older. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) SJIA, or Still's disease, is a rare, potentially life-threatening disorder in children that causes severe inflammation throughout the...

2011-03-30 17:04:40

The American College of Rheumatology has developed new guidelines for starting and monitoring treatments for children with juvenile idiopathic arthritis. These are the first JIA guidelines endorsed by the ACR, with the goal of broad acceptance within the rheumatology community. Created as a guide for health care providers, the guidelines focus on the initiation and safety monitoring of multiple medications used in the treatment of JIA, including:     * Non-steroidal...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin